Pharmacovigilance – Products

AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma

resDetect™ is a series of reagent kits designed to follow international legal and regulatory requirements and guidelines for the detection of residual components in the biopharmaceutical manufacturing process.

ProBioGen, is pleased to announce the execution of services and license agreements with MAPP BIOPHARMACEUTICAL, INC. to develop a cell line for an afucosylated antibody targeting Marburg virus (MARV) infection.

This whitepaper explores the latest advancements in OOC platforms that can help to efficiently simulate drug toxicity responses.

AMSBIO has expanded its range of products and services dedicated to assisting scientists diversify their preclinical models effectively to help bridge the gender discrepancy gap in many areas of research.

Study demonstrates proof-of-concept and strong safety profile of Aurase Wound Gel in patients suffering from chronic wounds.

N4 Pharma PLC (AIM: N4P), recently acquired a controlling interest in Nanogenics Limited.

This app note highlights an assay that enables streamlined, sensitive detection and characterization of mitochondrial toxicants.

Ontology will improve substance identification, cross-border prescriptions, regulatory process integration with manufacturers, supply-chain analytics, and pharmacovigilance.